+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-07-01Number of Pages: 110

Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous Antibacterials, and Pipeline Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

An antibacterial drug is referred to as an antimicrobial agent interfering with the growth and reproduction of bacteria that cause numerous mild to severe infections in humans and animals. Antibacterial drugs either kill or inhibit their growth. These agents possess bactericidal activity which target various parts of bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections. Antibacterial drugs are being in use since the discovery of the first antibacterial in the form of penicillin in 1928, and presently a wide range of antibacterials in several formulations are commercially available and used for the treatment of various indications like pneumonia, tuberculosis, tetanus, diphtheria, diarrhea, legionellosis and other diseases.

The global antibacterial drugs market has been categorized into eight segments based on their class which include: aminoglycosides, β-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides, phenicols, and miscellaneous antibacterials. In 2014, β-lactams occupied the leading position with a share of 57.7% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness a decline in their market share during the forecast period due to scheduled patent expiry of key branded formulations, coupled with growing number of drug resistant bacterial strains and increasing influx of generic drugs. Hence, on account of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2015 to 2023. However, the miscellaneous antibacterials segment is expected to grow with the highest CAGR accompanied with growing demand for therapies against bacterial infections and rising geriatric populations are some of the factors that are anticipated to maintain the growth of the antibacterial drugs market. Additionally, expected commercialization of various antibacterial agents that are currently in developmental stages, such as solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.) MK-3415A (Merck & Co.) during the forecast period is also expected to profound impact on growth of this market.

Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market in 2014. This region is also expected to experience the highest growth rate during the forecast period 2015 to 2023. The major factors responsible for this region to hold leadership in this market in 2014 include presence of large number of generic manufacturers  and active pharmaceutical ingredient (API) manufacturers in Asian countries, growing incidences of bacterial infections such as MRSA (methicillin resistant Staphylococcus aureus) and tuberculosis and increasing purchasing power of the domestic population. Moreover, developing health care infrastructure, presence of a large population base and growing geriatric population which is more prone to diseases would consequently increase the uptake of antibacterial drugs in Asia. North America held the second largest revenue share followed by Europe in the antibacterial drugs market in 2014. Market maturity, shortened product lifecycle, stringent regulatory requirements and generic infiltration are some of the factors that accounted for slow growth of this market.

AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Allergen plc, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the most promising and leading player in the Antibacterial drugs market. Major customers for their antibacterial drugs include hospitals, private clinics, physicians and patients.

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs,namely,aminoglycosides,B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides, phenicols and miscellaneous antibacterials. The market for each of these classes has been extensively analyzed on the basis of leading drug launch, patent expiry, drug efficacy, annual sales revenue and geography wise regulatory approval. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2013 to 2023, considering 2013 and 2014 as the historical and base year respectively, while the market forecast has been provided for the period 2015 to 2023. The report on antibacterial drugs market also provides compounded annual growth rate (CAGR) for each market segment for the forecast period 2015 to 2023.

 

Geographically, the antibacterial drugs market has been categorized into five regions, namely, North America, Europe, Asia Pacific, Latin America and Rest of the World (ROW). Each of these geographies have been further segmented with respect to major countries; where North America is segmented in U.S. and Canada, Europe is segmented in U.K., Germany and rest of Europe, Asia Pacific is segmented in China, Japan and rest of Asia Pacific, and Latin America is segmented in Brazil and rest of Latin America. The report also comprises a section on pipeline analysis, which provides sales forecast for various drugs currently under phase III clinical trials and are expected to be launched during the forecast period. Forecast of seventeen pipeline drugs has been provided since their launch in the U.S., till 2023. Apart from the quantitative information, the report also provides details on various qualitative factors impacting the antibacterial market trends such as drug recalls, black box warning, changes in regulatory policies, drug patent expiry and subsequent launch of generics and others. 

 

The research study also incorporates competitive scenario in the considered regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global antibacterial drugs market, and future opportunities has been provided in the market overview section. This section of the report also provides detailed market attractiveness analysis for major geographies. The analysis considers factors such as level of competition, interference of government and regulatory agencies, available customer base and future potential. The global antibacterial drugs market report includes a chapter on competitive landscape which provides market share analysis by leading players in the antibacterial drugs market, in terms of percent share in the year 2014. The report also includes event impact analysis, which provides a holistic view of new drug approvals in the market. A list of recommendations has also been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. 

 

The report also profiles major players in the antibacterial drugs market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Allergan plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. Novartis AG, Pfizer, Inc., and Sanofi. 

 

The global antibacterial drugs market is segmented as follows:

 

Global Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD Million)

  • Aminoglycosides
  • B-Lactams
  • Tetracyclines
  • Sulfonamides
  • Quinolones/Fluoroquinolones
  • Macrolides
  • Phenicols
  • Miscellaneous Antibacterials

Pipeline Analysis of Antibacterial Drugs Market

  • Actoxumab/Aezlotoxumab, (MK-3415A)
  • Surotomycin (MK-4261)
  • Arikace
  • Cadazolid 
  • Ciprofloxacin/Fluocinolone Acetonide 
  • Zempia (E-101)
  • Carbavance (meropenem/RPX7009)
  • Ozenoxacin
  • RHB-105
  • SPL7013
  • Delafloxacin
  • Solithromycin (CEM-101)
  • Eravacycline
  • Delamanid 
  • SYM-1219
  • Omadacycline (PTK-0796)
  • Plazomycin

Global Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World (RoW)


 
 
Back To Top